All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How can the unique structure of the bispecific ABBV-383 impact its safety and efficacy?

Featured
Jan 12, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in relapsed/refractory MM

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Shaji Kumar, Mayo Clinic, Rochester, US. We asked, How can the unique structure of the bispecific ABBV-383 impact its safety and efficacy?

How can the unique structure of the bispecific ABBV-383 impact its safety and efficacy?

In this video interview, Kumar considers the structure of ABBV-383, a B-cell maturation antigen (BCMA)/CD3 targeted bispecific antibody. ABBV-383 is unique in that it contains two BCMA binding domains, as well as a low-affinity binding domain to CD3. Kumar considers how this unique structure allows for effective myeloma cell death as well as reducing off-target toxicity, then goes on to outline the results presented at ASH 2022 from the phase I trial entitled: A phase 1 first-in-human study of ABBV-383, a BCMA × CD3 bispecific T-cell-redirecting antibody, as monotherapy in patients with relapsed/refractory multiple myeloma. Kumar focuses on the optimal dosage as well as the safety and efficacy profiles as established in this trial.

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox